Key result
Targeting voltage-gated potassium channels (KV) with antibodies constitutes a promising approach for cancer therapy.
Why the study?
Altered potassium channel expression correlates with malignancy and poor prognosis in many cancers, making targeting voltage-gated potassium channels a promising therapeutic approach.
Targeting voltage-gated potassium channels with antibodies represents a promising approach for cancer therapy.
Should not yet alter cancer management; leaves open the need for clinical validation of KV antibody targeting.
Voltage-gated potassium channels are transmembrane proteins that allow flow of potassium across the membrane to regulate ion homeostasis, cell proliferation, migration, cell volume, and specific processes such as muscular contraction. Aberrant function or expression of potassium channels can underlie pathologies ranging from heart arrhythmia to cancer; the expression of potassium channels is altered in many types of cancer and that alteration correlates with malignancy and poor prognosis. Targeting potassium channels therefore constitutes a promising approach for cancer therapy. In this review, we discuss strategies to target a particular family of potassium channels, the voltage-gated potassium channels (KV) where a reasonable structural understanding is available. We also discuss the possible obstacles and advantages of such a strategy.
No takes yet. Share an insight, caveat, or question.
Hernández‐Reséndiz et al. (2019) conducted a review in Cancer. Antibodies targeting KV potassium channels was evaluated. Targeting voltage-gated potassium channels (KV) with antibodies constitutes a promising approach for cancer therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: